<DOC>
	<DOCNO>NCT00824382</DOCNO>
	<brief_summary>The primary objective study determine optimum dose ( ) BI 1744 CL inhalation solution deliver Respimat inhaler daily 4 week Japanese patient chronic obstructive pulmonary disease ( COPD ) . The selection optimum dose ( ) base bronchodilator efficacy , safety evaluation pharmacokinetic evaluation .</brief_summary>
	<brief_title>Efficacy Safety 4 Weeks Treatment With Inhaled BI 1744 CL Japanese Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent GCP guideline prior participation trial . 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction postbronchodilator FEV1 &gt; =30 % predict normal &lt; 80 % predict normal postbronchodilator FEV1/FVC &lt; 70 % Visit 1 3 . Male female patient , 40 year age old 4 . Patients must current exsmokers smoke history 10 packyears . PackYears = [ Number cigarettes/day/20 ] â€” year smoke Patients never smoke cigarette must exclude . 5 . Patients must able perform technically acceptable pulmonary function test ( supervise unsupervised ) PEFR measurement , must able record patient diary study period require protocol . 6 . Patients must able inhale medication competent manner Respimat inhaler MDI . 1 . Patients significant disease COPD ; significant disease define disease , opinion investigator , may ) put patient risk participation study ii ) influence result study , iii ) cause concern regard patient 's ability participate study 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; patient AST &gt; 80 IU/L , ALT &gt; 80 IU/L , bilirubin &gt; 1.5 x ULN creatinine &gt; 1.5 x ULN exclude regardless clinical condition ( repeat laboratory evaluation conduct patient ) 3 . Patients history asthma total blood eosinophil count &gt; =600/mm3 . A repeat eosinophil count conduct patient 4 . Patients follow condition : diagnosis thyrotoxicosis diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) mark baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) recommend ICH E14 . For patient QTc interval 450 m 500 m , judge site personnel , confirmatory reading centralize evaluation institute . If confirmatory reading still great 450 m , patient exclude . Patients QTc interval &gt; =500 m immediately exclude study . history additional risk factor Torsade de Pointes ( TdP ) ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) recommend ICH E14 . 5 . Patients follow condition : history myocardial infarction within 1 year diagnosis clinically relevant cardiac arrhythmia know active tuberculosis malignancy patient undergone resection , radiation therapy chemotherapy within last 5 year ( patient treat basal cell carcinoma allow ) history lifethreatening pulmonary obstruction history cystic fibrosis clinically evident bronchiectasis history significant alcohol drug abuse 6 . Patients undergone thoracotomy pulmonary resection ( patient history thoracotomy reason evaluate per exclusion criterion No . 1 ) 7 . Patients treat follow concomitant medication : medication prolong QT/QTc interval oral betaadrenergics betaadrenergics patch betablockers ( topical betablockers ocular condition allow ) oral corticosteroid medication unstable dos ( i.e . le 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 8 . Patients regularly use daytime oxygen therapy 1 hour per day investigator 's opinion unable abstain use oxygen therapy clinic visit 9 . Patients complete pulmonary rehabilitation program 6 week prior screen visit ( Visit 1 ) patient currently pulmonary rehabilitation program 10 . Patients take investigational drug within 1 month 6 half life ( whichever great ) prior screen visit 11 . Patients know hypersensitivity betaadrenergics drug , BAC , EDTA component Respimat inhalation solution delivery system 12 . Pregnant suspect pregnant woman willing become pregnant study period nurse woman 13 . Patients previously participate study currently participate another study 14 . Patients unable comply pulmonary medication restriction prior randomisation 15 . The randomization patient respiratory infection COPD exacerbation 6 week prior screen visit screen period postpone . Patients may randomise 6 week follow recovery infection exacerbation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>